argenx (ARGX) vs Royalty Pharma (RPRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
Royalty Pharma (RPRX) has outperformed argenx (ARGX) over the past year, gaining 57.2% versus a gain of 16.5%. Over five years, ARGX leads with a +216.2% price change compared with +47.9% for RPRX. argenx is the larger company by market cap ($57.74 billion vs $32.80 billion), about 1.8 times the size.
On valuation, Royalty Pharma trades at a lower forward P/E (9.9x vs 26.7x for argenx). Royalty Pharma pays a dividend yielding 1.60%, while argenx does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | RPRX |
|---|---|---|
| Share price | $928.44 | $56.76 |
| Market cap | $57.74B | $32.80B |
| 1-day change | -0.22% | +0.57% |
| YTD return | +10.46% | +46.89% |
| 1-year return | +16.50% | +57.23% |
| 5-year return | +216.24% | +47.85% |
| P/E ratio (TTM) | 35.38 | 30.19 |
| Forward P/E | 26.74 | 9.90 |
| EPS (TTM) | $26.24 | $1.88 |
| Dividend yield | 0.00% | 1.60% |
| Annual dividend | $0.00 | $0.91 |
| Revenue (latest FY) | — | $2.38B |
| Revenue growth (YoY) | — | +5.06% |
| Net income (latest FY) | $1.29B | $770.95M |
| Operating margin | — | 65.58% |
| Net margin | — | 32.42% |
| 52-week high | $1,072.75 | $64.38 |
| 52-week low | $661.85 | $35.23 |
| Distance from 52-week high | -13.45% | -11.84% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +27.12% | +15.19% |
| Average volume | 283.20K | 2.92M |
| Shares outstanding | 62.19M | 445.28M |
| Employees | 1,863 | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RPRX has outperformed ARGX by 40.7 percentage points over the past year.
- Royalty Pharma offers a meaningfully higher dividend yield (1.60% vs 0.00%).
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About Royalty Pharma
RPRX stock →Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
ARGX vs RPRX FAQ
Which is bigger, argenx or Royalty Pharma?
argenx (ARGX) is larger, with a market capitalization of $57.74B compared with $32.80B for Royalty Pharma (RPRX).
Which stock has performed better over the past year, ARGX or RPRX?
RPRX returned +57.23% over the past 12 months, compared with +16.50% for ARGX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARGX or RPRX?
RPRX has the lower trailing P/E at 30.2, versus 35.4 for ARGX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, argenx or Royalty Pharma?
Royalty Pharma pays a dividend yielding 1.60%, while argenx does not currently pay a regular dividend.
Are argenx and Royalty Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for argenx and Biotechnology: Pharmaceutical Preparations for Royalty Pharma.